Accéder au contenu
Merck

SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.

Cell reports (2013-07-23)
Jacqueline Gire O'Rourke, Jaclyn R Gareau, Joseph Ochaba, Wan Song, Tamás Raskó, David Reverter, John Lee, Alex Mas Monteys, Judit Pallos, Lisa Mee, Malini Vashishtha, Barbara L Apostol, Thomas Peter Nicholson, Katalin Illes, Ya-Zhen Zhu, Mary Dasso, Gillian P Bates, Marian Difiglia, Beverly Davidson, Erich E Wanker, J Lawrence Marsh, Christopher D Lima, Joan S Steffan, Leslie M Thompson
RÉSUMÉ

A key feature in Huntington disease (HD) is the accumulation of mutant Huntingtin (HTT) protein, which may be regulated by posttranslational modifications. Here, we define the primary sites of SUMO modification in the amino-terminal domain of HTT, show modification downstream of this domain, and demonstrate that HTT is modified by the stress-inducible SUMO-2. A systematic study of E3 SUMO ligases demonstrates that PIAS1 is an E3 SUMO ligase for both HTT SUMO-1 and SUMO-2 modification and that reduction of dPIAS in a mutant HTT Drosophila model is protective. SUMO-2 modification regulates accumulation of insoluble HTT in HeLa cells in a manner that mimics proteasome inhibition and can be modulated by overexpression and acute knockdown of PIAS1. Finally, the accumulation of SUMO-2-modified proteins in the insoluble fraction of HD postmortem striata implicates SUMO-2 modification in the age-related pathogenic accumulation of mutant HTT and other cellular proteins that occurs during HD progression.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal de souris anti-c-Myc antibody produced in mouse, clone 9E10, purified from hybridoma cell culture